Visceral leishmaniasis is an infectious parasitic disease caused by the protozoan parasites Leishmania donovani and Leishmania infantum. The drugs currently used to treat visceral leishmaniasis suffer from toxicity and the emergence of parasite resistance, and so a better solution would be the development of an effective subunit vaccine; however, no approved vaccine currently exists. The comparative testing of a large number of vaccine candidates requires a quantitative and reproducible experimental murine infection model, but the parameters that influence infection pathology have not been systematically determined. to address this, we have established an infection model using a transgenic luciferaseexpressing L. donovani parasite and longitudinally quantified the infections using in vivo bioluminescent imaging within individual mice. We examined the effects of varying the infection route, the site of adjuvant formulation administration, and standardised the parasite preparation and dose. We observed that the increase in parasite load within the liver during the first few weeks of infection was directly proportional to the parasite number in the initial inoculum. finally, we show that immunity can be induced in pre-exposed animals that have resolved an initial infection. this murine infection model provides a platform for systematic subunit vaccine testing against visceral leishmaniasis.Protozoa of the genus Leishmania are obligate intracellular parasites which cause the disease leishmaniasis. The parasite is transmitted by the bite of an infected female phlebotomine sand fly during a blood meal, and every year there are an estimated ~1 million new infections resulting in ~65,000 deaths 1 . Although the disease burden disproportionately affects poor people living in tropical and developing countries, the expanding geographic range of vector distribution caused by climate and environmental changes is an emerging threat outside these regions 2-4 . Outbreaks and re-emergence of leishmaniasis are also linked to other factors including political and socioeconomic upheavals 5-7 . Within the human host, Leishmania spp. cause a spectrum of species-specific clinical manifestations known as cutaneous, mucocutaneous or visceral leishmaniases, and it is the visceral form that is considered to be the most severe, and is ultimately fatal if left untreated. Symptomatic visceral leishmaniasis (VL), results from infections of L. donovani and L. infantum, and while representing only ~10% of all symptomatic leishmanial infections, they are responsible for nearly all leishmaniasis-attributed fatalities 1 . The current front-line drug treatments for VL: liposomal amphotericin B, miltefosine, paromomycin and antimonials, are far from ideal, with major concerns surrounding general toxicity or increased treatment failure 8,9 . While improved drugs are being developed 10,11 , the deployment of an effective vaccine would be an important disease control tool, but to date, no effective vaccine has been licensed for human leishmaniasis.The e...